Loading...

FITC anti-human CD8a Antibody

Pricing & Availability
Clone
RPA-T8 (See other available formats)
Regulatory Status
RUO
Workshop
IV T171
Other Names
T8, Leu2
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
RPA-T8_FITC_060807
Human peripheral blood lymphocytes stained with RPA-T8 FITC
  • RPA-T8_FITC_060807
    Human peripheral blood lymphocytes stained with RPA-T8 FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
301005 25 tests 18€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301006 100 tests 40€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301060 100 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
301050 500 tests 164€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8a is a 32-34 kD type I glycoprotein. It forms a homodimer (CD8a/a) or heterodimer (CD8a/b) with CD8b. CD8, also known as T8 and Leu2, is a member of the immunoglobulin superfamily found on the majority of thymocytes, a subset of peripheral blood T cells, and NK cells (which express almost exclusively CD8a homodimers). CD8 acts as a co-receptor with MHC class I-restricted T cell receptors in antigen recognition and T cell activation, and has been shown to play a role in thymic differentiation. Two domains in CD8a are important for function: the extracellular IgSF domain binds the α3 domain of MHC class I and the cytoplasmic CXCP motif binds the tyrosine kinase p56 Lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human,Cynomolgus,Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

The RPA-T8 antibody does not block the binding of HIT8a antibody to CD8a. Additional reported applications of this antibody (for the relevant formats) include: immunohistochemical staining of paraformaldehyde-fixed frozen sections3 and costimulation of T cell responses4. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 301073 & 301074).

Application References
  1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
  3. Mack CL, et al. 2004. Pediatr. Res. 56:79. (IHC)
  4. Magidovich E, et al. 2007. P. Natl. Acad. Sci. USA 104:13022.
  5. Thakarl D, et al. 2008.J. immunol. 180:7431. PubMed
  6. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed
  7. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
  10. Stoeckius M, et al. 2017. Nat. Methods. 14:865. (PG)
Product Citations
  1. Termini J, et al. 2017. J Virol. 10.1128/JVI.00950-17. PubMed
  2. Franchini DM et al. 2019. Cell reports. 26(1):94-107 . PubMed
  3. Rodriguez‐Meira A et al. 2019. Molecular cell. 73(6):1292-1305 . PubMed
  4. Wallstabe L et al. 2019. JCI Insight. 4(18) pii: 126345. PubMed
  5. Zhang D, et al. 2020. Oncoimmunology. 9:1744921. PubMed
  6. Luo X, et al. 2020. Front Immunol. 11:623. PubMed
  7. Sashihara J, et al. 2011. PLoS One. 6:e1002308. PubMed
  8. Tamai Y, et al. 2013. J Immunol. 190:4382. PubMed
  9. Shi Z, et al. 2009. Eur J Immunol. 39:2106. PubMed
  10. Poonia B, Pauza C 2014. PLoS One. 9:88884. PubMed
  11. Chandran P, et al. 2014. J Leukoc Biol. 96:633. PubMed
  12. Castro I, et al. 2016. J Virol. 90: 5280 - 5291. PubMed
  13. Rodriguez-Meira A, et al. 2020. STAR Protoc. 1:100125. PubMed
  14. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  15. Danzer H, et al. 2020. Elife. 9:00. PubMed
  16. Landgraf KE, et al. 2020. Commun Biol. 0.330555556. PubMed
  17. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
  18. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  19. Louka E, et al. 2021. Journal of Experimental Medicine. 218(2):. PubMed
  20. Tian X, et al. 2021. Annals of Translational Medicine. 9(9):781. PubMed
  21. Mndez-Mancilla A, et al. 2021. Cell Chemical Biology. 29:321. PubMed
  22. Kan S, et al. 2020. Int J Oncol. 57:1047. PubMed
  23. Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed
  24. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
  25. Nakasone H, et al. 2021. Commun Biol. 4:1177. PubMed
  26. Bartok O, et al. 2020. Nature. . PubMed
  27. Zhang Y, et al. 2022. Front Immunol. 12:799206. PubMed
  28. Costa-Martins AG, et al. 2021. Cell Rep Med. 2:100465. PubMed
  29. Georg P, et al. 2022. Cell. 185:493. PubMed
  30. Haruna M, et al. 2020. Biol Pharm Bull. 43:399. PubMed
  31. Port JR, et al. 2020. J Virol. 94:. PubMed
  32. Vaurs J, et al. 2021. Sci Rep. 11:17234. PubMed
  33. Kenney DJ, et al. 2022. Cell Rep. 39:110714. PubMed
  34. Ogishi M, et al. 2023. J Exp Med. 220: . PubMed
  35. McEvoy CM, et al. 2022. Nat Commun. 13:7634. PubMed
  36. Meyer S, et al. 2023. Cell Rep. 42:111995. PubMed
  37. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  38. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
RRID
AB_314123 (BioLegend Cat. No. 301005)
AB_314124 (BioLegend Cat. No. 301006)
AB_2564165 (BioLegend Cat. No. 301060)
AB_2562055 (BioLegend Cat. No. 301050)

Antigen Details

Structure
Ig superfamily, homodimer or heterodimer with CD8β, 32-34 kD
Distribution

Majority of thymocytes, T cell subset, NK cells

Function
MHC class I co-receptor, thymic differentiation, T cell activation
Ligand/Receptor
MHC Class I molecules
Cell Type
Dendritic cells, NK cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay N, et al. 1993. The Leucocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
925 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org
Go To Top Version: 3    Revision Date: 07/13/2015

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account